Pages that link to "Q40124442"
Jump to navigation
Jump to search
The following pages link to KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway (Q40124442):
Displaying 50 items.
- Targeted therapy of gastrointestinal stromal tumours (Q26745633) (← links)
- Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions (Q26799387) (← links)
- Hyperplasia of interstitial cells of cajal in sprouty homolog 4 deficient mice (Q27308910) (← links)
- A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal (Q27851995) (← links)
- Small molecule modifier screen for kit-dependent functions in zebrafish embryonic melanocytes (Q28468692) (← links)
- p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors (Q28483922) (← links)
- PI3K pathway alterations in cancer: variations on a theme (Q29615530) (← links)
- Cyclin H expression is increased in GIST with very-high risk of malignancy (Q33624209) (← links)
- Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib. (Q33644791) (← links)
- Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line (Q33825096) (← links)
- Anti-apoptotic effects of osteopontin through the up-regulation of Mcl-1 in gastrointestinal stromal tumors (Q33841673) (← links)
- Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. (Q33906093) (← links)
- Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy (Q34029127) (← links)
- Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. (Q34620781) (← links)
- Gastrointestinal stromal tumours: origin and molecular oncology. (Q34633714) (← links)
- Major Response to Everolimus in Melanoma With Acquired Imatinib Resistance (Q34634269) (← links)
- Succinate dehydrogenase-deficient gastrointestinal stromal tumors (Q34668378) (← links)
- Oncogenic Kit signals on endolysosomes and endoplasmic reticulum are essential for neoplastic mast cell proliferation (Q34833416) (← links)
- Gastrointestinal stromal tumor - an evolving concept (Q34928165) (← links)
- Prognostic significance of promyelocytic leukemia expression in gastrointestinal stromal tumor; integrated proteomic and transcriptomic analysis (Q35051310) (← links)
- Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance (Q35143027) (← links)
- Identification of kinases and regulatory proteins required for cell migration using a transfected cell-microarray system (Q35194120) (← links)
- Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models (Q35555471) (← links)
- The current state of targeted therapy in melanoma: this time it's personal (Q35878248) (← links)
- Prognostic significance of PTEN, Ki-67 and CD44s expression patterns in gastrointestinal stromal tumors (Q35886697) (← links)
- Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors (Q35915389) (← links)
- KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation (Q36025994) (← links)
- Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors (Q36180074) (← links)
- M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells. (Q36344903) (← links)
- Primordial germ cells and gastrointestinal stromal tumors respond distinctly to a cKit overactivating allele (Q36477671) (← links)
- Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS) (Q36561734) (← links)
- KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors (Q36738831) (← links)
- Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment (Q36844334) (← links)
- DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors. (Q36959577) (← links)
- Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors? (Q36970527) (← links)
- Heterogeneity of kinase inhibitor resistance mechanisms in GIST (Q37218711) (← links)
- Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies (Q37220191) (← links)
- Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib (Q37324621) (← links)
- Imatinib treatment for gastrointestinal stromal tumour (GIST). (Q37334993) (← links)
- New therapeutic approaches for advanced gastrointestinal stromal tumors (Q37403036) (← links)
- Optimizing imatinib mesylate treatment in gastrointestinal stromal tumors (Q37408631) (← links)
- Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy (Q37605787) (← links)
- Recent advances in the treatment of gastrointestinal stromal tumors (Q37704347) (← links)
- Prognostic impact of gastrointestinal bleeding and expression of PTEN and Ki-67 on primary gastrointestinal stromal tumors (Q37710557) (← links)
- Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma (Q37727061) (← links)
- BRAF, a target in melanoma: implications for solid tumor drug development (Q37772444) (← links)
- Targeted therapy in GIST: in silico modeling for prediction of resistance (Q37848666) (← links)
- New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors: present and future (Q37850810) (← links)
- Systemic therapy for advanced gastrointestinal stromal tumors: Beyond imatinib (Q37954207) (← links)
- Therapeutic targeting of c-KIT in cancer (Q38057806) (← links)